Brokerages Expect Lipocine Inc. (LPCN) Will Post Earnings of -$0.30 Per Share

Equities analysts expect Lipocine Inc. (NASDAQ:LPCN) to post earnings per share (EPS) of ($0.30) for the current quarter, Zacks reports. Zero analysts have made estimates for Lipocine’s earnings. Lipocine posted earnings per share of ($0.16) in the same quarter last year, which would indicate a negative year over year growth rate of 87.5%. The firm is scheduled to announce its next earnings report on Monday, March 5th.

On average, analysts expect that Lipocine will report full-year earnings of ($1.06) per share for the current year, with EPS estimates ranging from ($1.11) to ($1.01). For the next fiscal year, analysts forecast that the company will report earnings of ($0.36) per share, with EPS estimates ranging from ($0.97) to $0.25. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Lipocine.

A number of research analysts recently commented on the company. Canaccord Genuity set a $11.00 target price on Lipocine and gave the company a “buy” rating in a research note on Monday, August 7th. ValuEngine lowered Lipocine from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Finally, Roth Capital set a $38.00 target price on Lipocine and gave the company a “buy” rating in a research note on Thursday, August 10th.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock valued at $362,000 after purchasing an additional 6,191 shares in the last quarter. KCG Holdings Inc. raised its stake in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock valued at $131,000 after purchasing an additional 7,219 shares in the last quarter. Federated Investors Inc. PA raised its stake in Lipocine by 9.2% during the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after acquiring an additional 7,429 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in Lipocine by 27.1% during the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock worth $229,000 after acquiring an additional 12,518 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Lipocine by 18.2% during the second quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after acquiring an additional 24,000 shares in the last quarter. Institutional investors and hedge funds own 22.06% of the company’s stock.

Shares of Lipocine (LPCN) traded down $0.01 during mid-day trading on Thursday, hitting $3.56. The stock had a trading volume of 132,236 shares, compared to its average volume of 134,160. Lipocine has a one year low of $3.25 and a one year high of $5.33.

COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Lipocine Inc. (LPCN) Will Post Earnings of -$0.30 Per Share” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.com-unik.info/2017/12/03/brokerages-expect-lipocine-inc-lpcn-will-post-earnings-of-0-30-per-share.html.

About Lipocine

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get a free copy of the Zacks research report on Lipocine (LPCN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lipocine (NASDAQ:LPCN)

What are top analysts saying about Lipocine Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lipocine Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit